MicroRNA-5572 Is Associated with Endoplasmic Reticulum Stress Responses in Low Zinc Treated and SOD1 G85R-Transfected HEK293 Cells.


Journal

Biological & pharmaceutical bulletin
ISSN: 1347-5215
Titre abrégé: Biol Pharm Bull
Pays: Japan
ID NLM: 9311984

Informations de publication

Date de publication:
2024
Historique:
medline: 28 10 2024
pubmed: 28 10 2024
entrez: 27 10 2024
Statut: ppublish

Résumé

Amyotrophic lateral sclerosis (ALS) is a fetal neurodegenerative disease. The mechanism of sporadic ALS onset remains unclarified in detail. Disruption of zinc homeostasis could be related to sporadic ALS. Previously, we first reported miR-5572 as a microRNA (miRNA) among those identified in the spinal cords of patients with sporadic ALS. However, since its function in ALS remained unknown, this study further examined the role of miR-5572 in low-zinc status and ALS model cells which transfected with causative gene, Cu/Zn superoxide dismutase 1 (SOD1) G85R mutant vector. The miR-5572 level was increased by low-zinc condition accompanied by increase of endoplasmic reticulum (ER) stress. In addition, increase of miR-5572 enhanced the cellular toxicity induced by low-zinc treatment. The expression of miR-5572 was also increased, which was accompanied by an increase of ER stress markers associated with SOD1 aggregation formation. Cell death and ER stress makers levels induced by tunicamycin treatment were further increased in miR-5572 mimic-transfected cells. This study showed that miR-5572 exacerbated ER stress toxicity associated with low-zinc status and mutant SOD1 aggregates in ALS.

Identifiants

pubmed: 39462586
doi: 10.1248/bpb.b24-00418
doi:

Substances chimiques

MicroRNAs 0
Superoxide Dismutase-1 EC 1.15.1.1
Zinc J41CSQ7QDS
SOD1 protein, human 0
Tunicamycin 11089-65-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1717-1725

Auteurs

Hisaka Kurita (H)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University.

Naoki Hirasawa (N)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University.

Saori Yabe (S)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University.

Ayu Okuda (A)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University.

Takanori Murakami (T)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University.

Kazuki Ohuchi (K)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University.

Aya Ogata (A)

Department of Pharmacy, Faculty of Pharmacy, Gifu University of Medical Science.

Hiroki Yoshioka (H)

Department of Pharmacy, Faculty of Pharmacy, Gifu University of Medical Science.
Department of Hygiene, School of Medicine, Kitasato University.

Akiyoshi Kakita (A)

Department of Pathology, Brain Research Institute, Niigata University.

Isao Hozumi (I)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University.

Masatoshi Inden (M)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH